SlideShare a Scribd company logo
UPDATES IN DIAGNOSIS &UPDATES IN DIAGNOSIS &
TREATMENT OF OSTEOPOROSISTREATMENT OF OSTEOPOROSIS
Dr Shahjada SelimDr Shahjada Selim
Assistant ProfessorAssistant Professor
Department of Endocrinology & MetabolismDepartment of Endocrinology & Metabolism
Bangabandhu Sheikh Mujib Medical UniversityBangabandhu Sheikh Mujib Medical University
Dhaka, BangladeeshDhaka, Bangladeesh
OsteoporosisOsteoporosis
Osteoporosis is defined as a low bone massOsteoporosis is defined as a low bone mass
with bone mass with bone arcitechturoulwith bone mass with bone arcitechturoul
deformity.deformity.
NIH Consensus Development Conference, March 2000NIH Consensus Development Conference, March 2000
Normal Bone Osteoporotic Bone
Vertebral Fracture Cascade
THE HUMAN COSTTHE HUMAN COST
Downward SpiralDownward Spiral
Definition of a Fragility FractureDefinition of a Fragility Fracture
A fragility fracture is one that resultsA fragility fracture is one that results
from mechanical forces that wouldfrom mechanical forces that would
not ordinarily cause fracture in anot ordinarily cause fracture in a
healthy young adult.healthy young adult.
This is quantified as forcesThis is quantified as forces
equivalent to a fall from a standingequivalent to a fall from a standing
height or less.height or less.
OsteoporosisOsteoporosis
8 million Osteoporotic Women and 2.5 million Osteoporotic Men in USA8 million Osteoporotic Women and 2.5 million Osteoporotic Men in USA
Expected to increase by about 40% by 2020Expected to increase by about 40% by 2020 11
EstimatedEstimated DirectDirect costs in 2001 = $ 11.6 - 17.1 billion annuallycosts in 2001 = $ 11.6 - 17.1 billion annually 11
Based on relative older Canadian populationBased on relative older Canadian population 22
&&
Australian estimates of 7:1 ratio for Indirect to direct costsAustralian estimates of 7:1 ratio for Indirect to direct costs 33
⇒⇒ $6 - $40 million every single day in Canada$6 - $40 million every single day in Canada
Mortality increased 2-3 fold in women and womenMortality increased 2-3 fold in women and women
after all types of Osteoporotic fracturesafter all types of Osteoporotic fractures 44
1
Surgeon-Generals Report
2
Canadian and US census data
3
Access Economics, 4
Center 1999
Prevalence of VCF’sPrevalence of VCF’s
Lifetime prevalence in Caucasians:Lifetime prevalence in Caucasians:
15% in women15% in women
5-9% in men5-9% in men
Higher than risk of breast cancerHigher than risk of breast cancer
Osteoporotic fractures, Cardiovascular events &Osteoporotic fractures, Cardiovascular events &
Breast cancerBreast cancer
in osteoporotic postmenopausal womenin osteoporotic postmenopausal women
Any fracture
Spine #
Clinical Spine #
Hip fracture
CVS event
Breast
Cancer
No prior spine fracture (938)
Prior spine fracture (1627)
0
20
40
60
80
100
120
from Silverman et al, 2004
J Am Geriatr Soc 52:1543-8
Events
per 1000
women-yr
MORE study
placebo arm
over 3 years
SITESITE INCREASE ININCREASE IN
MORTALITY RISKMORTALITY RISK
VertebraeVertebrae 8.68.6
HipHip 6.76.7
Any Clinical FractureAny Clinical Fracture 2.22.2
Fracture and Mortality Risk
Each year, one in three Ontarians over the age
of 65 will take a serious tumble that may land
them in hospital with a broken hip. One in three
of those who do break their hip will die within
a year. Two thirds will experience dementia-like
symptoms. Most will never see home again.
Osteoporosis-associatedOsteoporosis-associated
MortalityMortality
Age-standardised mortality riskAge-standardised mortality risk
increased 2-3 foldincreased 2-3 fold
after all types of osteoporotic fractureafter all types of osteoporotic fracture
WomenWomen MenMen
Proximal femurProximal femur 2.22.2 3.23.2
VertebralVertebral 1.71.7 2.42.4
Other majorOther major 1.91.9 2.22.2
Center et al, Lancet 1999
““THE CARE GAP”THE CARE GAP”
IN OSTEOPOROSISIN OSTEOPOROSIS
Despite the introduction of methods toDespite the introduction of methods to
identify those with osteoporosis andidentify those with osteoporosis and
despite effective treatment, a largedespite effective treatment, a large
‘care gap’ continues to exist for these‘care gap’ continues to exist for these
patients.patients.
THE TIP OF THE ICEBERG
ASSESSMENT
MANAGEMENT
Recommendations for BoneRecommendations for Bone
Mineral Density Reporting inMineral Density Reporting in
CanadaCanada..
Siminoski K, Leslie WD, Brown JP, Frame H, Hodsman A,
Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G
Can Assoc Radiol J 2005; 56: 178-188
2002 Definitions: BMD Results2002 Definitions: BMD Results
1. Kanis JA, et al. J Bone Miner Res 1994;9:1137-1141.
2. WHO, Geneva 1994.
StatusStatus 1, 21, 2 T-scoreT-score
NormalNormal +2.5 to+2.5 to −−1.0, inclusive1.0, inclusive
OsteopeniaOsteopenia BetweenBetween −−1.0 and1.0 and −−2.52.5
OsteoporosisOsteoporosis ≤−≤−2.52.5
Severe osteoporosisSevere osteoporosis ≤−≤−2.5 + fragility fracture2.5 + fragility fracture
ABOUTABOUT
T-SCORES?T-SCORES?
Advantages
Unitless
Basis for the majority of
osteoporosis guidelines
Simplicity
Disadvantages
Depends on site measured
Depends on technology
Depends on reference
database—population mean
and standard deviation
Only includes BMD
information and not additional
risk factors
Adapted from Faulkner K. Osteoporos Int 2005;16(4):347-52.
Fracture RiskFracture Risk
vs. BMDvs. BMD
At Different AgesAt Different Ages
Fracture RiskFracture Risk
vs. BMDvs. BMD
At Different AgesAt Different Ages
BMD PREDICTS FRACTURESBMD PREDICTS FRACTURES
Hui et al. J Clin Invest 1988; 81:1804-9
AGEAGE T-ScoreT-Score
= -1.0= -1.0
T-ScoreT-Score
= -2.5= -2.5
5050 6 %6 % 11 %11 %
6060 8 %8 % 16 %16 %
7070 12 %12 % 23 %23 %
8080 13 %13 % 26 %26 %
Risk of Fractures Over 10 Years in WomenRisk of Fractures Over 10 Years in Women
Proposed ChangeProposed Change
Previous OSC guidelines advised interventionPrevious OSC guidelines advised intervention
based on WHO category as a marker of relativebased on WHO category as a marker of relative
fracture risk.fracture risk.
Now propose that anNow propose that an individual’s 10-yearindividual’s 10-year
absolute fracture riskabsolute fracture risk, rather than BMD alone,, rather than BMD alone,
be used for fracture risk categorizationbe used for fracture risk categorization
5-STEPS IN5-STEPS IN
TREATING OSTEOPOROSISTREATING OSTEOPOROSIS
STEPS 1 and 2STEPS 1 and 2
Begin with the table appropriate forBegin with the table appropriate for
the patient’s sexthe patient’s sex
Identify the row that is closest toIdentify the row that is closest to
the patient's agethe patient's age
CATEGORIZATION BASED ON 10-YEARCATEGORIZATION BASED ON 10-YEAR
FRACTURE RISKFRACTURE RISK
Absolute fracture risk in 10 years:Absolute fracture risk in 10 years:
low:low: <10%<10%
moderate:moderate: 10-20%10-20%
high:high: >20%>20%
USING LOWEST T-SCORE TO FIND 10-YEARUSING LOWEST T-SCORE TO FIND 10-YEAR
FRACTURE RISK - WOMENFRACTURE RISK - WOMEN
WOMEN
-4.5
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
50 55 60 65 70 75 80 85
AGE (years)
LOWESTT-Score
Moderate RiskModerate Risk
High RiskHigh Risk
Low Risk
5-STEPS IN5-STEPS IN
TREATING OSTEOPOROSISTREATING OSTEOPOROSIS
STEP 3STEP 3
Determine the preliminary fracture riskDetermine the preliminary fracture risk
category by using the lowest T-scorecategory by using the lowest T-score
from the recommended skeletal sitesfrom the recommended skeletal sites
5-STEPS IN5-STEPS IN
TREATING OSTEOPOROSISTREATING OSTEOPOROSIS
STEP 4STEP 4
Evaluate clinical factors that may moveEvaluate clinical factors that may move
the patient into an even higher fracturethe patient into an even higher fracture
risk categoryrisk category
USING LOWEST T-SCORE TO FIND 10-YEARUSING LOWEST T-SCORE TO FIND 10-YEAR
FRACTURE RISK - MENFRACTURE RISK - MEN
MEN
-4.5
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
50 55 60 65 70 75 80 85
AGE (years)
LOWESTT-Score
Low RiskLow Risk
High RiskHigh Risk
Moderate RiskModerate Risk
Additional Clinical FactorsAdditional Clinical Factors
Certain clinical factors increase fractureCertain clinical factors increase fracture
risk independent of BMD.risk independent of BMD.
The most important are:The most important are:
– Fragility fractures after age 40 (especiallyFragility fractures after age 40 (especially
vertebral compression fractures)vertebral compression fractures)
– Systemic glucocorticoid therapy >3 monthsSystemic glucocorticoid therapy >3 months
duration.duration.
Additional Risk FactorsAdditional Risk Factors
Each factor effectively increases riskEach factor effectively increases risk
categorization to the next level:categorization to the next level:
– from low risk to moderate risk, orfrom low risk to moderate risk, or
– from moderate risk to high riskfrom moderate risk to high risk
When both factors are present theWhen both factors are present the
patient should be considered at highpatient should be considered at high
risk regardless of the BMD result.risk regardless of the BMD result.
5-STEPS IN5-STEPS IN
TREATING OSTEOPOROSISTREATING OSTEOPOROSIS
STEP 5STEP 5
Determine the individual’s finalDetermine the individual’s final
absolute fracture risk category.absolute fracture risk category.
Woman – age 52Woman – age 52
- t is -2.6- t is -2.6
Fracture Risk Category?Fracture Risk Category?
CASE EXAMPLECASE EXAMPLE
High RiskHigh Risk
Moderate RiskModerate Risk
Low RiskLow Risk
WOMEN
-4.5
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
50 55 60 65 70 75 80 85
AGE (years)
LOWESTT-Score CASE EXAMPLECASE EXAMPLE
Low Risk
Moderate Risk
High Risk
AGE LOW MODERATE HIGH
<10% 10 to 20% >20%
50 >-2.3 -2.2 to -3.9 <-3.9
55 >-1.9 1.9 to -3.4 <-3.4
60 >-1.4 -1.4 to -3.0 <-3.0
65 >-1.0 -1.0 to -2.6 <-2.6
70 >-0.8 -0.8 to -2.2 <-2.2
75 >-0.7 -0.7 to -2.1 <-2.1
80 >-0.6 -0.6 to -2.0 <-2.0
85 >-0.7 -0.7 to -2.2 <-2.2
10-YEAR RISK
WOMEN
CASE EXAMPLECASE EXAMPLE
-2.2- -3.9
Fracture Risk CategoryFracture Risk Category
Moderate RiskModerate Risk
CASE EXAMPLECASE EXAMPLE
Fracture Risk CategoryFracture Risk Category
High RiskHigh Risk
Moderate RiskModerate Risk
If Fragility Fracture HistoryIf Fragility Fracture History
CASE EXAMPLECASE EXAMPLE
70 year-old man70 year-old man
CASE EXAMPLECASE EXAMPLE
Lowest T-score –2.7 in total hipLowest T-score –2.7 in total hip
BMD done because of strong familyBMD done because of strong family
history of osteoporosishistory of osteoporosis (mother fractured hip, sister(mother fractured hip, sister
has OP)has OP)
USING LOWEST T-SCORE TO FIND 10-YEARUSING LOWEST T-SCORE TO FIND 10-YEAR
FRACTURE RISK - MENFRACTURE RISK - MEN
MEN
-4.5
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
50 55 60 65 70 75 80 85
AGE (years)
LOWESTT-Score
Low RiskLow Risk
High RiskHigh Risk
Moderate RiskModerate Risk
X
Fracture Risk CategoryFracture Risk Category
Moderate RiskModerate Risk
CASE EXAMPLECASE EXAMPLE
OTHER ISSUES FOR THIS 70OTHER ISSUES FOR THIS 70
YEAR OLD MALEYEAR OLD MALE
Chest x-ray – mild loss of vertebral heightChest x-ray – mild loss of vertebral height
at T4, T5at T4, T5
What if he had had polymyalgiaWhat if he had had polymyalgia
rheumatica at age 69 and was onrheumatica at age 69 and was on
prednisone 10 mg./day?prednisone 10 mg./day?
Fracture Risk CategoryFracture Risk Category
Moderate RiskModerate Risk
If Fragility Fracture History,If Fragility Fracture History,
Corticosteroid useCorticosteroid use
High RiskHigh Risk
CASE EXAMPLECASE EXAMPLE
EndorsementsEndorsements
Canadian Association of Nuclear MedicineCanadian Association of Nuclear Medicine
Canadian Association of RadiologistsCanadian Association of Radiologists
Canadian Rheumatology AssociationCanadian Rheumatology Association
International Society of Clinical DensitometryInternational Society of Clinical Densitometry
Society of Obstetricians and Gynecologists of CanadaSociety of Obstetricians and Gynecologists of Canada
Canadian Society of Endocrinology and MetabolismCanadian Society of Endocrinology and Metabolism
Canadian Orthopedic AssociationCanadian Orthopedic Association
College of Family Physicians of CanadaCollege of Family Physicians of Canada
Osteoporosis Prevention andOsteoporosis Prevention and
TreatmentTreatment
Age
Hormonal Replacement
Bisphosphonates
Strontium
SERM
20 40 60 80
Vitamin D
PTH
Life Style
Treatment
choice
** with prev vert fracture(s)with prev vert fracture(s) **** without prev vert fractureswithout prev vert fractures ****** with or without prev verfractureswith or without prev verfractures
Antifracture efficacy of antiosteoporotic agents
0.6 1.00.2
Incident nonvertebral fractures
Relative risk
RLX 60, 120
(MORE)***
CT 200 (PROOF)*
Teriparatide 20µg*
ALN 5/10 (FIT1)*
ALN 5/10 (FIT2)**
RIS 5 (VERT-NA)*
RIS 5 (VERT-MN)*
RIS 2.5/5 (Hip Study)***RIS 2.5/5 (Hip Study)***
Incident vertebral fractures
Relative risk
0.60.6 1.01.00.20.2
RLX 60 (MORE)*
RLX 60 (MORE)**
CT 200 (PROOF)*
Teriparatide 20µg*
ALN 5/10 (FIT1)*
ALN 5/10 (FIT2)**
RIS 5 (VERT-NA)*
RIS 5 (VERT-MN)*
Strontium ranelate
(SOTI)*
Strontium ranelate
(SOTI +TROPOS)**
Strontium ranelate
(TROPOS)***
Strontium ranelate
(SOTI)*
Updated from Delmas, Lancet 2002
RR ± 95% CI
Medications Available forMedications Available for
Post-Menopausal OsteoporosisPost-Menopausal Osteoporosis
ActonelActonel®®
(risedronate sodium tablets) (1/day;1/wk; 1/mo)(risedronate sodium tablets) (1/day;1/wk; 1/mo)
Didrocal® (etidronate sodium tablets)Didrocal® (etidronate sodium tablets)
FosamaxFosamax®®
(alendronate sodium tablets) 1day/1/wk; Fosovance)(alendronate sodium tablets) 1day/1/wk; Fosovance)
AclastaAclasta ®®
(zolendronate IV)(zolendronate IV)
Estrogen (some use)Estrogen (some use)
EvistaEvista®®
(raloxifene HCl)(raloxifene HCl)
MiacalcinMiacalcin®®
(calcitonin salmon) Nasal Spray(calcitonin salmon) Nasal Spray
Forteo (Teriparatide) (sc)Forteo (Teriparatide) (sc)
Consult with your physician to determine what medication mayConsult with your physician to determine what medication may
be best for yoube best for you
Bisphosphonates — CyclicalBisphosphonates — Cyclical
EtidronateEtidronate
pp=NS=NS
00
1010
2020
3030
4040
5050
1818
Etidronate (n = 20)Etidronate (n = 20)
4343
Placebo (n = 20)Placebo (n = 20)
LumbarspinefracturerateLumbarspinefracturerate
(fractures/100patient-years(fractures/100patient-years))
Storm T.Storm T. N Engl J MedN Engl J Med 1990;1990;322322:1265.:1265.
• 3-year RCT, 66 subjects3-year RCT, 66 subjects
• High risk subgroup: reduction in fracture rate with etidronate,High risk subgroup: reduction in fracture rate with etidronate, pp = 0.023= 0.023
• No statistically significant effect at nonvertebral sitesNo statistically significant effect at nonvertebral sites
Cumulative Hip FractureCumulative Hip Fracture
IncidenceIncidence
Baseline Month 6 Month 12
%ofcohortwithahipfracture
0.00
0.10
0.20
0.30
0.40
0.50
0.58
alendronate
risedronate
Silverman SL. Osteoporos Int 2007 Jan;18(1):25-34. Epub 2006 Nov 15.
↓ 43%*
Adjusted Relative Rate
Reduction at Month 12
p = 0.01
95% CI: 13% - 63%
↓ 46%*
Adjusted Relative Rate
Reduction at Month 6
p = 0.02
95% CI: 9% - 68%
80 fractures
n= 21,615
29 fractures
n = 12,215
Osteoporosis in MenOsteoporosis in Men
Has Its Time Come?Has Its Time Come?
HEADLINESHEADLINES
7.8.077.8.07
HIP FRACTURESHIP FRACTURES
MORBIDITY AND MORTALITYMORBIDITY AND MORTALITY
“One-third of all hip fractures occur in men and are
associated with as much illness and increased risk
of death as those that occur in women .”
“The average 50-year-old Caucasian man has a 13
per cent chance of having a fracture related to
osteoporosis sometime in his remaining lifetime. A
60-year-old Caucasian man has a 29 per cent
chance.”
Dr. John Schousboe, Minneapolis 2007
Male Osteoporosis: Morbidity andMale Osteoporosis: Morbidity and
MortalityMortality
As compared to women, while lifetimeAs compared to women, while lifetime
fracture risk may be less,fracture risk may be less,
– Men have higher rates of morbidity andMen have higher rates of morbidity and
mortality due to fracturesmortality due to fractures
– Men are twice as likely to die in hospital afterMen are twice as likely to die in hospital after
a hip fracturea hip fracture
– Men have a higher mortality rate than womenMen have a higher mortality rate than women
one year after a hip fractureone year after a hip fracture
Cooper C, et al. Osteoporos Int 1992;2:285-9; Singer BR, et al. J Bone Joint Surg
Br 1998;80:243-8; Center JR, et al. The Lancet 1999;353:878-82; Forsen L, et al.
Osteoporos Int 1999;10:73-8; Johnell O., et al. Calcif Tissue Int 2001;69:182-4;
Amin S. Curr Osteoporos Rep 2003;1:71-7; Campion JM, et al. Am Fam Phys
GLUCOCORTICOIDS and BONEGLUCOCORTICOIDS and BONE
Have a reflex! SGC > 3 mo > 7.5 mg./dayHave a reflex! SGC > 3 mo > 7.5 mg./day
-Ca, vitamin D, bisphosphonate-Ca, vitamin D, bisphosphonate
Bone density evaluation?Bone density evaluation?
Back injuries.Back injuries. If you think that golf is for wimps, considerIf you think that golf is for wimps, consider
this: Athis: A golf swinggolf swing puts a higher compressive load on theputs a higher compressive load on the
low back (low back (8 times body weight8 times body weight) than) than runningrunning ((33 timestimes) or) or
eveneven rowingrowing ((77 timestimes). That’s why a single swing can). That’s why a single swing can
produce a herniated disc or even aproduce a herniated disc or even a compressioncompression fracturefracture
of one of the vertebral bodies. Although these injuriesof one of the vertebral bodies. Although these injuries
are extremely painful and can be quite serious, they areare extremely painful and can be quite serious, they are
rare. Muscle strains, however, are quite commonrare. Muscle strains, however, are quite common
because of the twisting that is required for a good swing.because of the twisting that is required for a good swing.
The “modern” swing, with its inverted-C follow-through,The “modern” swing, with its inverted-C follow-through,
may make for longer drives than the “classic” swing but itmay make for longer drives than the “classic” swing but it
also produces more torque — and more injuries (also produces more torque — and more injuries (seesee
Golf injuriesGolf injuries aboveabove).).
Harvard Men’s Health Watch Aug 2004
SUMMARYSUMMARY
REDUCING THE ‘CARE GAP’REDUCING THE ‘CARE GAP’
Assess bone health in woman >50 and inAssess bone health in woman >50 and in
men > 60.men > 60.
Evaluate risk factors; evaluate BMDEvaluate risk factors; evaluate BMD
Consider preventative approach toConsider preventative approach to
reduction of fracture risk (the way youreduction of fracture risk (the way you
think of hypertension and MI and stroke)think of hypertension and MI and stroke)
Treat and monitorTreat and monitor

More Related Content

What's hot

Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...
Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...
Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...National Osteoporosis Society
 
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...National Osteoporosis Society
 
Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...
Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...
Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...Apollo Hospitals
 
Conquering challenges in op mgt & treatment
Conquering challenges in op mgt & treatmentConquering challenges in op mgt & treatment
Conquering challenges in op mgt & treatmentIhsaan Peer
 
Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...
Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...
Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...National Osteoporosis Society
 
Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...
Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...
Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...National Osteoporosis Society
 
Breast cancer a focus on bone health integrity
Breast cancer  a focus on bone health integrityBreast cancer  a focus on bone health integrity
Breast cancer a focus on bone health integrityMohamed Abdulla
 
Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...
Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...
Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...National Osteoporosis Society
 
Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016
Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016
Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016National Osteoporosis Society
 
Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...
Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...
Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...National Osteoporosis Society
 

What's hot (20)

Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...
Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...
Osteoporosis 2016 | From family history to epigenetics of osteoporosis: Dr Ni...
 
Assessing Fracture Risk
Assessing Fracture RiskAssessing Fracture Risk
Assessing Fracture Risk
 
Risk assessment
Risk assessmentRisk assessment
Risk assessment
 
Is my treatment working doctor?
Is my treatment working doctor?Is my treatment working doctor?
Is my treatment working doctor?
 
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
Osteoporosis 2016 | Patients receiving bisphosphonates should not take holida...
 
Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...
Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...
Multiple atraumatic osteoporotic vertebral fractures: Unusual cause of pain i...
 
Conquering challenges in op mgt & treatment
Conquering challenges in op mgt & treatmentConquering challenges in op mgt & treatment
Conquering challenges in op mgt & treatment
 
Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...
Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...
Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo...
 
Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...
Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...
Osteoporosis 2016 | Patients receiving bisphosphonates should take holidays f...
 
Osteoporosis an update-Dr Selim
Osteoporosis an update-Dr SelimOsteoporosis an update-Dr Selim
Osteoporosis an update-Dr Selim
 
Seminar 28-11-2015 Prof. Dr. W.F. Lems
Seminar 28-11-2015 Prof. Dr. W.F. LemsSeminar 28-11-2015 Prof. Dr. W.F. Lems
Seminar 28-11-2015 Prof. Dr. W.F. Lems
 
Breast cancer a focus on bone health integrity
Breast cancer  a focus on bone health integrityBreast cancer  a focus on bone health integrity
Breast cancer a focus on bone health integrity
 
Oite 9.14.2010
Oite 9.14.2010Oite 9.14.2010
Oite 9.14.2010
 
Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...
Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...
Osteoporosis 2016 | Day-to-day levels of high impact physical activity are po...
 
Rheumatology Highlights 2012
Rheumatology Highlights 2012Rheumatology Highlights 2012
Rheumatology Highlights 2012
 
Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016
Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016
Osteoporosis 2016 | Scope Of The Problem: Prof. Elaine Dennison #osteo2016
 
Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...
Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...
Osteoporosis 2016 | Fracture Risk assessment tools: Prof. Eugene McCloskey #o...
 
Osteoporosis
 Osteoporosis Osteoporosis
Osteoporosis
 
Oite 2010 disease
Oite 2010 diseaseOite 2010 disease
Oite 2010 disease
 
Osteoprosis: Evaluation, Management and Prevention by Dr Shahjada Selim
Osteoprosis: Evaluation, Management and Prevention by Dr Shahjada SelimOsteoprosis: Evaluation, Management and Prevention by Dr Shahjada Selim
Osteoprosis: Evaluation, Management and Prevention by Dr Shahjada Selim
 

Viewers also liked

Prevent osteoporosis
Prevent osteoporosisPrevent osteoporosis
Prevent osteoporosisjwdweck
 
Osteoporosis treatment strategy using bisphosphonate once a year
Osteoporosis treatment strategy using bisphosphonate once a yearOsteoporosis treatment strategy using bisphosphonate once a year
Osteoporosis treatment strategy using bisphosphonate once a yearRachmat Gunadi Wachjudi
 
The treatment of osteoporosis
The treatment of osteoporosis The treatment of osteoporosis
The treatment of osteoporosis Vince Chang
 
Thoraco Lumbar Spine Injury
Thoraco Lumbar Spine InjuryThoraco Lumbar Spine Injury
Thoraco Lumbar Spine InjuryKevin Ambadan
 
Thoraco lumbar fractures of spine
Thoraco lumbar fractures of spine Thoraco lumbar fractures of spine
Thoraco lumbar fractures of spine Sunil Santhosh
 
Osteoporosis, Diagnosis and treatment
Osteoporosis, Diagnosis and treatmentOsteoporosis, Diagnosis and treatment
Osteoporosis, Diagnosis and treatmentStalin Chowdary
 

Viewers also liked (11)

Prevent osteoporosis
Prevent osteoporosisPrevent osteoporosis
Prevent osteoporosis
 
Insulin initiation adjustment by Dr Shahjada Selim
Insulin initiation adjustment by Dr Shahjada SelimInsulin initiation adjustment by Dr Shahjada Selim
Insulin initiation adjustment by Dr Shahjada Selim
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Osteoporosis treatment strategy using bisphosphonate once a year
Osteoporosis treatment strategy using bisphosphonate once a yearOsteoporosis treatment strategy using bisphosphonate once a year
Osteoporosis treatment strategy using bisphosphonate once a year
 
The treatment of osteoporosis
The treatment of osteoporosis The treatment of osteoporosis
The treatment of osteoporosis
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Thoraco Lumbar Spine Injury
Thoraco Lumbar Spine InjuryThoraco Lumbar Spine Injury
Thoraco Lumbar Spine Injury
 
Thoraco lumbar fractures of spine
Thoraco lumbar fractures of spine Thoraco lumbar fractures of spine
Thoraco lumbar fractures of spine
 
Osteoporosis, Diagnosis and treatment
Osteoporosis, Diagnosis and treatmentOsteoporosis, Diagnosis and treatment
Osteoporosis, Diagnosis and treatment
 
Osteoporosis Seminar
Osteoporosis Seminar Osteoporosis Seminar
Osteoporosis Seminar
 

Similar to Dr selim updates on osteoporosis

Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)
Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)
Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)Rachmat Gunadi Wachjudi
 
Ckd-MBD & osteoporosis the management dilemma
Ckd-MBD  & osteoporosis the management dilemma Ckd-MBD  & osteoporosis the management dilemma
Ckd-MBD & osteoporosis the management dilemma Ayman Seddik
 
osteoporosis epidemiology and diagnosis
osteoporosis epidemiology and diagnosisosteoporosis epidemiology and diagnosis
osteoporosis epidemiology and diagnosisDilek Gogas Yavuz
 
Osteoporosis amgen meeting
Osteoporosis amgen meetingOsteoporosis amgen meeting
Osteoporosis amgen meetingIhsaan Peer
 
Cost-effective Treatment and Fracture Risk
Cost-effective Treatment and Fracture RiskCost-effective Treatment and Fracture Risk
Cost-effective Treatment and Fracture Riskdemiss
 
Managment of glucocorticoids induced osteoprosis
Managment of glucocorticoids induced osteoprosisManagment of glucocorticoids induced osteoprosis
Managment of glucocorticoids induced osteoprosisMarwa Besar
 
Management of osteoporosis
Management of osteoporosisManagement of osteoporosis
Management of osteoporosisAshok Bhatt
 
Osteoporosis%203rd%20yr[1]
Osteoporosis%203rd%20yr[1]Osteoporosis%203rd%20yr[1]
Osteoporosis%203rd%20yr[1]cotitoblue
 
Osteoporosis new horizons
Osteoporosis new horizonsOsteoporosis new horizons
Osteoporosis new horizonsShambhu N
 
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silentWay+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silentdhavalshah4424
 
2-Osteoporosis-Track-2.pptx
2-Osteoporosis-Track-2.pptx2-Osteoporosis-Track-2.pptx
2-Osteoporosis-Track-2.pptxMsccMohamed
 
Diagnosi e trattamento dell'osteoporosi
Diagnosi e trattamento dell'osteoporosiDiagnosi e trattamento dell'osteoporosi
Diagnosi e trattamento dell'osteoporosiASMaD
 
Dr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility Fractures
Dr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility FracturesDr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility Fractures
Dr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility FracturesSteven R. Goldstein
 
Guidelines for the management of Osteoporosis.pdf
Guidelines for the management of Osteoporosis.pdfGuidelines for the management of Osteoporosis.pdf
Guidelines for the management of Osteoporosis.pdfNaziaawan7
 

Similar to Dr selim updates on osteoporosis (20)

Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)
Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)
Osteoporosis treatment strategy using BMD and Clical Risk Factors (FRAX)
 
Osteoporosis diagnosis and treatment
Osteoporosis diagnosis and treatment Osteoporosis diagnosis and treatment
Osteoporosis diagnosis and treatment
 
Shafei osteoporosis
Shafei osteoporosisShafei osteoporosis
Shafei osteoporosis
 
Ckd-MBD & osteoporosis the management dilemma
Ckd-MBD  & osteoporosis the management dilemma Ckd-MBD  & osteoporosis the management dilemma
Ckd-MBD & osteoporosis the management dilemma
 
osteoporosis epidemiology and diagnosis
osteoporosis epidemiology and diagnosisosteoporosis epidemiology and diagnosis
osteoporosis epidemiology and diagnosis
 
Osteoporosis amgen meeting
Osteoporosis amgen meetingOsteoporosis amgen meeting
Osteoporosis amgen meeting
 
Capturing vertebral fractures - Dr Amit Gupta
Capturing vertebral fractures - Dr Amit GuptaCapturing vertebral fractures - Dr Amit Gupta
Capturing vertebral fractures - Dr Amit Gupta
 
Cost-effective Treatment and Fracture Risk
Cost-effective Treatment and Fracture RiskCost-effective Treatment and Fracture Risk
Cost-effective Treatment and Fracture Risk
 
Managment of glucocorticoids induced osteoprosis
Managment of glucocorticoids induced osteoprosisManagment of glucocorticoids induced osteoprosis
Managment of glucocorticoids induced osteoprosis
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Management of osteoporosis
Management of osteoporosisManagement of osteoporosis
Management of osteoporosis
 
Osteoporosis%203rd%20yr[1]
Osteoporosis%203rd%20yr[1]Osteoporosis%203rd%20yr[1]
Osteoporosis%203rd%20yr[1]
 
Osteoporosis new horizons
Osteoporosis new horizonsOsteoporosis new horizons
Osteoporosis new horizons
 
Osteoporosis
Osteoporosis Osteoporosis
Osteoporosis
 
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silentWay+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
 
2-Osteoporosis-Track-2.pptx
2-Osteoporosis-Track-2.pptx2-Osteoporosis-Track-2.pptx
2-Osteoporosis-Track-2.pptx
 
Diagnosi e trattamento dell'osteoporosi
Diagnosi e trattamento dell'osteoporosiDiagnosi e trattamento dell'osteoporosi
Diagnosi e trattamento dell'osteoporosi
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Dr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility Fractures
Dr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility FracturesDr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility Fractures
Dr Steven R. Goldstein - Osteoporosis, Poor Bone Health, Fragility Fractures
 
Guidelines for the management of Osteoporosis.pdf
Guidelines for the management of Osteoporosis.pdfGuidelines for the management of Osteoporosis.pdf
Guidelines for the management of Osteoporosis.pdf
 

More from Bangabandhu Sheikh Mujib Medical University

More from Bangabandhu Sheikh Mujib Medical University (20)

Future of DM management by Dr Shahjada Selim
Future of DM management by Dr Shahjada SelimFuture of DM management by Dr Shahjada Selim
Future of DM management by Dr Shahjada Selim
 
Gynecomastia by Dr Shahjada Selim
Gynecomastia by Dr Shahjada SelimGynecomastia by Dr Shahjada Selim
Gynecomastia by Dr Shahjada Selim
 
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimEmpagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
 
Managing Diabetes With Insulin by Dr Shahjada Selim
Managing DiabetesWith Insulin by Dr Shahjada SelimManaging DiabetesWith Insulin by Dr Shahjada Selim
Managing Diabetes With Insulin by Dr Shahjada Selim
 
Approach to optimal diabetes care by Dr Shahajda Selim
Approach to optimal diabetes care by Dr Shahajda SelimApproach to optimal diabetes care by Dr Shahajda Selim
Approach to optimal diabetes care by Dr Shahajda Selim
 
Overview of male infertility by Dr Dhahjada Selim
Overview of male infertility by Dr Dhahjada SelimOverview of male infertility by Dr Dhahjada Selim
Overview of male infertility by Dr Dhahjada Selim
 
Genetics to environment to T1DM by Dr Shahjada Selim
Genetics to environment to T1DM by Dr Shahjada SelimGenetics to environment to T1DM by Dr Shahjada Selim
Genetics to environment to T1DM by Dr Shahjada Selim
 
Type 1 Diabetes: Dr Shahjada Selim
Type 1 Diabetes: Dr Shahjada SelimType 1 Diabetes: Dr Shahjada Selim
Type 1 Diabetes: Dr Shahjada Selim
 
Thyroid disorders- an overview- Dr Shahjada Selim
Thyroid disorders- an overview- Dr Shahjada SelimThyroid disorders- an overview- Dr Shahjada Selim
Thyroid disorders- an overview- Dr Shahjada Selim
 
Thyroid Disorders in Pregnancy- Dr Shahjada Selim
Thyroid Disorders in Pregnancy- Dr Shahjada SelimThyroid Disorders in Pregnancy- Dr Shahjada Selim
Thyroid Disorders in Pregnancy- Dr Shahjada Selim
 
Erectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Erectile Dysfunction:Evaluation and Management by Dr Shahjada SelimErectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
Erectile Dysfunction:Evaluation and Management by Dr Shahjada Selim
 
Hypothyroidism: Evaluation & Management by Dr Selim
Hypothyroidism: Evaluation & Management by Dr SelimHypothyroidism: Evaluation & Management by Dr Selim
Hypothyroidism: Evaluation & Management by Dr Selim
 
Sexual Response Cycle- Dr Shahjada Selim
Sexual Response Cycle- Dr Shahjada SelimSexual Response Cycle- Dr Shahjada Selim
Sexual Response Cycle- Dr Shahjada Selim
 
Diabetes and Sexual Dysfunction -Dr Shahjada Seliml
Diabetes and Sexual Dysfunction -Dr Shahjada SelimlDiabetes and Sexual Dysfunction -Dr Shahjada Seliml
Diabetes and Sexual Dysfunction -Dr Shahjada Seliml
 
Menopause Dr Shahjada Selim
Menopause Dr Shahjada SelimMenopause Dr Shahjada Selim
Menopause Dr Shahjada Selim
 
Menopause by Dr Shahjada Selim
Menopause by Dr Shahjada SelimMenopause by Dr Shahjada Selim
Menopause by Dr Shahjada Selim
 
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada SelimMenopausal Hormone Replacement Therapy by Dr Shahjada Selim
Menopausal Hormone Replacement Therapy by Dr Shahjada Selim
 
Diagnostic Tests of Diabetes
Diagnostic Tests of DiabetesDiagnostic Tests of Diabetes
Diagnostic Tests of Diabetes
 
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada SelimMale Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
Male Sexual Dysfunction: Evaluation and Management by Dr Shahjada Selim
 
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada SelimVitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
Vitamin D and Immunity: COVID-19 Perspectives by Dr Shahjada Selim
 

Recently uploaded

Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMeenakshiGursamy
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgeryKafrELShiekh University
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Catherine Liao
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghanahealthwatchghana
 
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLSlakehe2738
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfDr Jeenal Mistry
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...kevinkariuki227
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadNephroTube - Dr.Gawad
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...kevinkariuki227
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyDr KHALID B.M
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feeldranji1
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...kevinkariuki227
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Catherine Liao
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Catherine Liao
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Catherine Liao
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxgauripg8
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCatherine Liao
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...Catherine Liao
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramLevi Shapiro
 

Recently uploaded (20)

Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 

Dr selim updates on osteoporosis

  • 1. UPDATES IN DIAGNOSIS &UPDATES IN DIAGNOSIS & TREATMENT OF OSTEOPOROSISTREATMENT OF OSTEOPOROSIS Dr Shahjada SelimDr Shahjada Selim Assistant ProfessorAssistant Professor Department of Endocrinology & MetabolismDepartment of Endocrinology & Metabolism Bangabandhu Sheikh Mujib Medical UniversityBangabandhu Sheikh Mujib Medical University Dhaka, BangladeeshDhaka, Bangladeesh
  • 2. OsteoporosisOsteoporosis Osteoporosis is defined as a low bone massOsteoporosis is defined as a low bone mass with bone mass with bone arcitechturoulwith bone mass with bone arcitechturoul deformity.deformity. NIH Consensus Development Conference, March 2000NIH Consensus Development Conference, March 2000 Normal Bone Osteoporotic Bone
  • 4. THE HUMAN COSTTHE HUMAN COST Downward SpiralDownward Spiral
  • 5. Definition of a Fragility FractureDefinition of a Fragility Fracture A fragility fracture is one that resultsA fragility fracture is one that results from mechanical forces that wouldfrom mechanical forces that would not ordinarily cause fracture in anot ordinarily cause fracture in a healthy young adult.healthy young adult. This is quantified as forcesThis is quantified as forces equivalent to a fall from a standingequivalent to a fall from a standing height or less.height or less.
  • 6. OsteoporosisOsteoporosis 8 million Osteoporotic Women and 2.5 million Osteoporotic Men in USA8 million Osteoporotic Women and 2.5 million Osteoporotic Men in USA Expected to increase by about 40% by 2020Expected to increase by about 40% by 2020 11 EstimatedEstimated DirectDirect costs in 2001 = $ 11.6 - 17.1 billion annuallycosts in 2001 = $ 11.6 - 17.1 billion annually 11 Based on relative older Canadian populationBased on relative older Canadian population 22 && Australian estimates of 7:1 ratio for Indirect to direct costsAustralian estimates of 7:1 ratio for Indirect to direct costs 33 ⇒⇒ $6 - $40 million every single day in Canada$6 - $40 million every single day in Canada Mortality increased 2-3 fold in women and womenMortality increased 2-3 fold in women and women after all types of Osteoporotic fracturesafter all types of Osteoporotic fractures 44 1 Surgeon-Generals Report 2 Canadian and US census data 3 Access Economics, 4 Center 1999
  • 7. Prevalence of VCF’sPrevalence of VCF’s Lifetime prevalence in Caucasians:Lifetime prevalence in Caucasians: 15% in women15% in women 5-9% in men5-9% in men Higher than risk of breast cancerHigher than risk of breast cancer
  • 8. Osteoporotic fractures, Cardiovascular events &Osteoporotic fractures, Cardiovascular events & Breast cancerBreast cancer in osteoporotic postmenopausal womenin osteoporotic postmenopausal women Any fracture Spine # Clinical Spine # Hip fracture CVS event Breast Cancer No prior spine fracture (938) Prior spine fracture (1627) 0 20 40 60 80 100 120 from Silverman et al, 2004 J Am Geriatr Soc 52:1543-8 Events per 1000 women-yr MORE study placebo arm over 3 years
  • 9. SITESITE INCREASE ININCREASE IN MORTALITY RISKMORTALITY RISK VertebraeVertebrae 8.68.6 HipHip 6.76.7 Any Clinical FractureAny Clinical Fracture 2.22.2 Fracture and Mortality Risk
  • 10. Each year, one in three Ontarians over the age of 65 will take a serious tumble that may land them in hospital with a broken hip. One in three of those who do break their hip will die within a year. Two thirds will experience dementia-like symptoms. Most will never see home again.
  • 11. Osteoporosis-associatedOsteoporosis-associated MortalityMortality Age-standardised mortality riskAge-standardised mortality risk increased 2-3 foldincreased 2-3 fold after all types of osteoporotic fractureafter all types of osteoporotic fracture WomenWomen MenMen Proximal femurProximal femur 2.22.2 3.23.2 VertebralVertebral 1.71.7 2.42.4 Other majorOther major 1.91.9 2.22.2 Center et al, Lancet 1999
  • 12. ““THE CARE GAP”THE CARE GAP” IN OSTEOPOROSISIN OSTEOPOROSIS Despite the introduction of methods toDespite the introduction of methods to identify those with osteoporosis andidentify those with osteoporosis and despite effective treatment, a largedespite effective treatment, a large ‘care gap’ continues to exist for these‘care gap’ continues to exist for these patients.patients.
  • 13. THE TIP OF THE ICEBERG ASSESSMENT MANAGEMENT
  • 14. Recommendations for BoneRecommendations for Bone Mineral Density Reporting inMineral Density Reporting in CanadaCanada.. Siminoski K, Leslie WD, Brown JP, Frame H, Hodsman A, Josse RG, Khan A, Lentle BC, Levesque J, Lyons DJ, Tarulli G Can Assoc Radiol J 2005; 56: 178-188
  • 15. 2002 Definitions: BMD Results2002 Definitions: BMD Results 1. Kanis JA, et al. J Bone Miner Res 1994;9:1137-1141. 2. WHO, Geneva 1994. StatusStatus 1, 21, 2 T-scoreT-score NormalNormal +2.5 to+2.5 to −−1.0, inclusive1.0, inclusive OsteopeniaOsteopenia BetweenBetween −−1.0 and1.0 and −−2.52.5 OsteoporosisOsteoporosis ≤−≤−2.52.5 Severe osteoporosisSevere osteoporosis ≤−≤−2.5 + fragility fracture2.5 + fragility fracture
  • 16. ABOUTABOUT T-SCORES?T-SCORES? Advantages Unitless Basis for the majority of osteoporosis guidelines Simplicity Disadvantages Depends on site measured Depends on technology Depends on reference database—population mean and standard deviation Only includes BMD information and not additional risk factors Adapted from Faulkner K. Osteoporos Int 2005;16(4):347-52.
  • 17. Fracture RiskFracture Risk vs. BMDvs. BMD At Different AgesAt Different Ages Fracture RiskFracture Risk vs. BMDvs. BMD At Different AgesAt Different Ages BMD PREDICTS FRACTURESBMD PREDICTS FRACTURES Hui et al. J Clin Invest 1988; 81:1804-9
  • 18. AGEAGE T-ScoreT-Score = -1.0= -1.0 T-ScoreT-Score = -2.5= -2.5 5050 6 %6 % 11 %11 % 6060 8 %8 % 16 %16 % 7070 12 %12 % 23 %23 % 8080 13 %13 % 26 %26 % Risk of Fractures Over 10 Years in WomenRisk of Fractures Over 10 Years in Women
  • 19. Proposed ChangeProposed Change Previous OSC guidelines advised interventionPrevious OSC guidelines advised intervention based on WHO category as a marker of relativebased on WHO category as a marker of relative fracture risk.fracture risk. Now propose that anNow propose that an individual’s 10-yearindividual’s 10-year absolute fracture riskabsolute fracture risk, rather than BMD alone,, rather than BMD alone, be used for fracture risk categorizationbe used for fracture risk categorization
  • 20. 5-STEPS IN5-STEPS IN TREATING OSTEOPOROSISTREATING OSTEOPOROSIS STEPS 1 and 2STEPS 1 and 2 Begin with the table appropriate forBegin with the table appropriate for the patient’s sexthe patient’s sex Identify the row that is closest toIdentify the row that is closest to the patient's agethe patient's age
  • 21. CATEGORIZATION BASED ON 10-YEARCATEGORIZATION BASED ON 10-YEAR FRACTURE RISKFRACTURE RISK Absolute fracture risk in 10 years:Absolute fracture risk in 10 years: low:low: <10%<10% moderate:moderate: 10-20%10-20% high:high: >20%>20%
  • 22. USING LOWEST T-SCORE TO FIND 10-YEARUSING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK - WOMENFRACTURE RISK - WOMEN WOMEN -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 50 55 60 65 70 75 80 85 AGE (years) LOWESTT-Score Moderate RiskModerate Risk High RiskHigh Risk Low Risk
  • 23. 5-STEPS IN5-STEPS IN TREATING OSTEOPOROSISTREATING OSTEOPOROSIS STEP 3STEP 3 Determine the preliminary fracture riskDetermine the preliminary fracture risk category by using the lowest T-scorecategory by using the lowest T-score from the recommended skeletal sitesfrom the recommended skeletal sites
  • 24. 5-STEPS IN5-STEPS IN TREATING OSTEOPOROSISTREATING OSTEOPOROSIS STEP 4STEP 4 Evaluate clinical factors that may moveEvaluate clinical factors that may move the patient into an even higher fracturethe patient into an even higher fracture risk categoryrisk category
  • 25. USING LOWEST T-SCORE TO FIND 10-YEARUSING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK - MENFRACTURE RISK - MEN MEN -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 50 55 60 65 70 75 80 85 AGE (years) LOWESTT-Score Low RiskLow Risk High RiskHigh Risk Moderate RiskModerate Risk
  • 26. Additional Clinical FactorsAdditional Clinical Factors Certain clinical factors increase fractureCertain clinical factors increase fracture risk independent of BMD.risk independent of BMD. The most important are:The most important are: – Fragility fractures after age 40 (especiallyFragility fractures after age 40 (especially vertebral compression fractures)vertebral compression fractures) – Systemic glucocorticoid therapy >3 monthsSystemic glucocorticoid therapy >3 months duration.duration.
  • 27. Additional Risk FactorsAdditional Risk Factors Each factor effectively increases riskEach factor effectively increases risk categorization to the next level:categorization to the next level: – from low risk to moderate risk, orfrom low risk to moderate risk, or – from moderate risk to high riskfrom moderate risk to high risk When both factors are present theWhen both factors are present the patient should be considered at highpatient should be considered at high risk regardless of the BMD result.risk regardless of the BMD result.
  • 28. 5-STEPS IN5-STEPS IN TREATING OSTEOPOROSISTREATING OSTEOPOROSIS STEP 5STEP 5 Determine the individual’s finalDetermine the individual’s final absolute fracture risk category.absolute fracture risk category.
  • 29. Woman – age 52Woman – age 52 - t is -2.6- t is -2.6 Fracture Risk Category?Fracture Risk Category? CASE EXAMPLECASE EXAMPLE
  • 30. High RiskHigh Risk Moderate RiskModerate Risk Low RiskLow Risk WOMEN -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 50 55 60 65 70 75 80 85 AGE (years) LOWESTT-Score CASE EXAMPLECASE EXAMPLE Low Risk Moderate Risk High Risk
  • 31. AGE LOW MODERATE HIGH <10% 10 to 20% >20% 50 >-2.3 -2.2 to -3.9 <-3.9 55 >-1.9 1.9 to -3.4 <-3.4 60 >-1.4 -1.4 to -3.0 <-3.0 65 >-1.0 -1.0 to -2.6 <-2.6 70 >-0.8 -0.8 to -2.2 <-2.2 75 >-0.7 -0.7 to -2.1 <-2.1 80 >-0.6 -0.6 to -2.0 <-2.0 85 >-0.7 -0.7 to -2.2 <-2.2 10-YEAR RISK WOMEN CASE EXAMPLECASE EXAMPLE -2.2- -3.9
  • 32. Fracture Risk CategoryFracture Risk Category Moderate RiskModerate Risk CASE EXAMPLECASE EXAMPLE
  • 33. Fracture Risk CategoryFracture Risk Category High RiskHigh Risk Moderate RiskModerate Risk If Fragility Fracture HistoryIf Fragility Fracture History CASE EXAMPLECASE EXAMPLE
  • 34. 70 year-old man70 year-old man CASE EXAMPLECASE EXAMPLE Lowest T-score –2.7 in total hipLowest T-score –2.7 in total hip BMD done because of strong familyBMD done because of strong family history of osteoporosishistory of osteoporosis (mother fractured hip, sister(mother fractured hip, sister has OP)has OP)
  • 35. USING LOWEST T-SCORE TO FIND 10-YEARUSING LOWEST T-SCORE TO FIND 10-YEAR FRACTURE RISK - MENFRACTURE RISK - MEN MEN -4.5 -4.0 -3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 50 55 60 65 70 75 80 85 AGE (years) LOWESTT-Score Low RiskLow Risk High RiskHigh Risk Moderate RiskModerate Risk X
  • 36. Fracture Risk CategoryFracture Risk Category Moderate RiskModerate Risk CASE EXAMPLECASE EXAMPLE
  • 37. OTHER ISSUES FOR THIS 70OTHER ISSUES FOR THIS 70 YEAR OLD MALEYEAR OLD MALE Chest x-ray – mild loss of vertebral heightChest x-ray – mild loss of vertebral height at T4, T5at T4, T5 What if he had had polymyalgiaWhat if he had had polymyalgia rheumatica at age 69 and was onrheumatica at age 69 and was on prednisone 10 mg./day?prednisone 10 mg./day?
  • 38. Fracture Risk CategoryFracture Risk Category Moderate RiskModerate Risk If Fragility Fracture History,If Fragility Fracture History, Corticosteroid useCorticosteroid use High RiskHigh Risk CASE EXAMPLECASE EXAMPLE
  • 39. EndorsementsEndorsements Canadian Association of Nuclear MedicineCanadian Association of Nuclear Medicine Canadian Association of RadiologistsCanadian Association of Radiologists Canadian Rheumatology AssociationCanadian Rheumatology Association International Society of Clinical DensitometryInternational Society of Clinical Densitometry Society of Obstetricians and Gynecologists of CanadaSociety of Obstetricians and Gynecologists of Canada Canadian Society of Endocrinology and MetabolismCanadian Society of Endocrinology and Metabolism Canadian Orthopedic AssociationCanadian Orthopedic Association College of Family Physicians of CanadaCollege of Family Physicians of Canada
  • 40. Osteoporosis Prevention andOsteoporosis Prevention and TreatmentTreatment Age Hormonal Replacement Bisphosphonates Strontium SERM 20 40 60 80 Vitamin D PTH Life Style Treatment choice
  • 41. ** with prev vert fracture(s)with prev vert fracture(s) **** without prev vert fractureswithout prev vert fractures ****** with or without prev verfractureswith or without prev verfractures Antifracture efficacy of antiosteoporotic agents 0.6 1.00.2 Incident nonvertebral fractures Relative risk RLX 60, 120 (MORE)*** CT 200 (PROOF)* Teriparatide 20µg* ALN 5/10 (FIT1)* ALN 5/10 (FIT2)** RIS 5 (VERT-NA)* RIS 5 (VERT-MN)* RIS 2.5/5 (Hip Study)***RIS 2.5/5 (Hip Study)*** Incident vertebral fractures Relative risk 0.60.6 1.01.00.20.2 RLX 60 (MORE)* RLX 60 (MORE)** CT 200 (PROOF)* Teriparatide 20µg* ALN 5/10 (FIT1)* ALN 5/10 (FIT2)** RIS 5 (VERT-NA)* RIS 5 (VERT-MN)* Strontium ranelate (SOTI)* Strontium ranelate (SOTI +TROPOS)** Strontium ranelate (TROPOS)*** Strontium ranelate (SOTI)* Updated from Delmas, Lancet 2002 RR ± 95% CI
  • 42. Medications Available forMedications Available for Post-Menopausal OsteoporosisPost-Menopausal Osteoporosis ActonelActonel®® (risedronate sodium tablets) (1/day;1/wk; 1/mo)(risedronate sodium tablets) (1/day;1/wk; 1/mo) Didrocal® (etidronate sodium tablets)Didrocal® (etidronate sodium tablets) FosamaxFosamax®® (alendronate sodium tablets) 1day/1/wk; Fosovance)(alendronate sodium tablets) 1day/1/wk; Fosovance) AclastaAclasta ®® (zolendronate IV)(zolendronate IV) Estrogen (some use)Estrogen (some use) EvistaEvista®® (raloxifene HCl)(raloxifene HCl) MiacalcinMiacalcin®® (calcitonin salmon) Nasal Spray(calcitonin salmon) Nasal Spray Forteo (Teriparatide) (sc)Forteo (Teriparatide) (sc) Consult with your physician to determine what medication mayConsult with your physician to determine what medication may be best for yoube best for you
  • 43. Bisphosphonates — CyclicalBisphosphonates — Cyclical EtidronateEtidronate pp=NS=NS 00 1010 2020 3030 4040 5050 1818 Etidronate (n = 20)Etidronate (n = 20) 4343 Placebo (n = 20)Placebo (n = 20) LumbarspinefracturerateLumbarspinefracturerate (fractures/100patient-years(fractures/100patient-years)) Storm T.Storm T. N Engl J MedN Engl J Med 1990;1990;322322:1265.:1265. • 3-year RCT, 66 subjects3-year RCT, 66 subjects • High risk subgroup: reduction in fracture rate with etidronate,High risk subgroup: reduction in fracture rate with etidronate, pp = 0.023= 0.023 • No statistically significant effect at nonvertebral sitesNo statistically significant effect at nonvertebral sites
  • 44. Cumulative Hip FractureCumulative Hip Fracture IncidenceIncidence Baseline Month 6 Month 12 %ofcohortwithahipfracture 0.00 0.10 0.20 0.30 0.40 0.50 0.58 alendronate risedronate Silverman SL. Osteoporos Int 2007 Jan;18(1):25-34. Epub 2006 Nov 15. ↓ 43%* Adjusted Relative Rate Reduction at Month 12 p = 0.01 95% CI: 13% - 63% ↓ 46%* Adjusted Relative Rate Reduction at Month 6 p = 0.02 95% CI: 9% - 68% 80 fractures n= 21,615 29 fractures n = 12,215
  • 45. Osteoporosis in MenOsteoporosis in Men Has Its Time Come?Has Its Time Come?
  • 47. HIP FRACTURESHIP FRACTURES MORBIDITY AND MORTALITYMORBIDITY AND MORTALITY “One-third of all hip fractures occur in men and are associated with as much illness and increased risk of death as those that occur in women .” “The average 50-year-old Caucasian man has a 13 per cent chance of having a fracture related to osteoporosis sometime in his remaining lifetime. A 60-year-old Caucasian man has a 29 per cent chance.” Dr. John Schousboe, Minneapolis 2007
  • 48. Male Osteoporosis: Morbidity andMale Osteoporosis: Morbidity and MortalityMortality As compared to women, while lifetimeAs compared to women, while lifetime fracture risk may be less,fracture risk may be less, – Men have higher rates of morbidity andMen have higher rates of morbidity and mortality due to fracturesmortality due to fractures – Men are twice as likely to die in hospital afterMen are twice as likely to die in hospital after a hip fracturea hip fracture – Men have a higher mortality rate than womenMen have a higher mortality rate than women one year after a hip fractureone year after a hip fracture Cooper C, et al. Osteoporos Int 1992;2:285-9; Singer BR, et al. J Bone Joint Surg Br 1998;80:243-8; Center JR, et al. The Lancet 1999;353:878-82; Forsen L, et al. Osteoporos Int 1999;10:73-8; Johnell O., et al. Calcif Tissue Int 2001;69:182-4; Amin S. Curr Osteoporos Rep 2003;1:71-7; Campion JM, et al. Am Fam Phys
  • 49. GLUCOCORTICOIDS and BONEGLUCOCORTICOIDS and BONE Have a reflex! SGC > 3 mo > 7.5 mg./dayHave a reflex! SGC > 3 mo > 7.5 mg./day -Ca, vitamin D, bisphosphonate-Ca, vitamin D, bisphosphonate Bone density evaluation?Bone density evaluation?
  • 50.
  • 51. Back injuries.Back injuries. If you think that golf is for wimps, considerIf you think that golf is for wimps, consider this: Athis: A golf swinggolf swing puts a higher compressive load on theputs a higher compressive load on the low back (low back (8 times body weight8 times body weight) than) than runningrunning ((33 timestimes) or) or eveneven rowingrowing ((77 timestimes). That’s why a single swing can). That’s why a single swing can produce a herniated disc or even aproduce a herniated disc or even a compressioncompression fracturefracture of one of the vertebral bodies. Although these injuriesof one of the vertebral bodies. Although these injuries are extremely painful and can be quite serious, they areare extremely painful and can be quite serious, they are rare. Muscle strains, however, are quite commonrare. Muscle strains, however, are quite common because of the twisting that is required for a good swing.because of the twisting that is required for a good swing. The “modern” swing, with its inverted-C follow-through,The “modern” swing, with its inverted-C follow-through, may make for longer drives than the “classic” swing but itmay make for longer drives than the “classic” swing but it also produces more torque — and more injuries (also produces more torque — and more injuries (seesee Golf injuriesGolf injuries aboveabove).). Harvard Men’s Health Watch Aug 2004
  • 52. SUMMARYSUMMARY REDUCING THE ‘CARE GAP’REDUCING THE ‘CARE GAP’ Assess bone health in woman >50 and inAssess bone health in woman >50 and in men > 60.men > 60. Evaluate risk factors; evaluate BMDEvaluate risk factors; evaluate BMD Consider preventative approach toConsider preventative approach to reduction of fracture risk (the way youreduction of fracture risk (the way you think of hypertension and MI and stroke)think of hypertension and MI and stroke) Treat and monitorTreat and monitor

Editor's Notes

  1. Osteoblastscan build but they can’t jump!
  2. Vertebral fractures are associated with: Altered spinal shape. Impaired physiological function, including a reduced lung function. Reduced mobility and ability to carry out activities of daily living. Chronic pain, social isolation, depression and altered quality of life. Once osteoporosis patients begin fracturing, they tend to continue to fracture, a natural history referred to by some as the fracture cascade, or, when talking about the spine only, the vertebral fracture cascade. Within the spine, once a fracture has occurred, this alters spinal dynamics further, making the individual prone to even more vertebral fractures. Many studies have now shown that all of the negative manifestations of vertebral fractures worsen as the number of fractures increases. This slide illustrates in pictorial form some of the stages a woman with osteoporosis might experience as she sustains increasing numbers of fractures over the years.
  3. Women get all excited about the C-word: they should be getting excited about the O word
  4. Speaker Notes: This presentation reviews the 2005 Osteoporosis Society of Canada’s “Recommendations for Bone Mineral Density Reporting”, published in the June 2005 edition of the Canadian Association of Radiologists journal. These recommendations were developed by a multidisciplinary working group under the auspices of the Scientific Advisory Council of the Osteoporosis Society of Canada and the Canadian Association of Radiologists. All recommendations were developed using a consensus from clinicians and experts in the field of BMD testing and a standard method for the evaluation and citation of the supporting evidence.
  5. Speaker Notes In 2002 the OSC adopted the World Health Organization (WHO) study group’s definitions for BMD reporting. These were based on comparing an individual patient with a mean BMD for a normal young adult population of the same sex and race. The definition assigns the patient a T-score, which is the number of standard deviations (SDs) the patient’s BMD is above or below the mean, as follows: – Normal: BMD T-score between +2.5 and −1.0,inclusive – Osteopenia (low BMD): BMD T-score between −1.0 and −2.5 – Osteoporosis: BMD T-score at or lower than −2.5. The WHO study group added a fourth category, severe osteoporosis, to describe patients whose T-score is at or below −2.5 and who also have suffered a fragility fracture. The WHO has defined a fragility fracture as “a fracture caused by injury that would be insufficient to fracture normal bone: the result of reduced compressive and/or torsional strength of bone.” Clinically, a fragility fracture may be defined as one that occurs as a result of minimal or no identifiable trauma.
  6. Speaker Notes:
  7. Speaker Notes: Earlier studies have identified the relationship between age, BMD and fracture risk
  8. Speaker Notes: Risk of Fractures Over 10 years in Women; This further illustrates the relationship of fracture risk and age. Note that in the absence of other risk factors, an 80 yr old woman with a T-score of –1.0 has a greater risk for fracture than a 50 yr old woman with a T-score of –2.5
  9. Speaker Notes: Previous OSC guidelines advised intervention based on WHO category as a marker of relative fracture risk. Now propose that an individual’s 10-year absolute fracture risk, rather than BMD alone, be used for fracture risk categorization Use the 5 Steps in Treating Osteoporosis Slides to further clarify
  10. Speaker Notes: Begin with the table appropriate for the patient’s sex Identify the row that is closest to the patient&amp;apos;s age Next slide shows tables for women and men
  11. The fracture risk category (low, moderate, high) is determined from the previous tables of corresponding T score and age. There are 3 categories for absolute risk: low (less than 10%, moderate (between 10-20%), and high (over 20%). Similar risk categories have been used for cardiovascular risk assessment.
  12. Speaker Notes: Patient’s score can be plotted on the graph and level of fracture risk identified
  13. Speaker Notes: Determine the preliminary fracture risk category by using the lowest T-score from the recommended skeletal sites
  14. Speaker Notes: Evaluate clinical factors that may move the patient into an even higher fracture risk category
  15. Speaker Notes: Certain risk factors increase fracture risk independent of BMD. The most important are: Fragility fractures after age 40 yrs (especially vertebral compression fractures) Systemic glucocorticoid therapy of &amp;gt;3months duration
  16. Speaker Notes: The presence of either of these factors substantially elevates fracture risk. Such factors effectively increase risk categorization to the next level: from low risk to moderate risk, or from moderate risk to high risk. When both factors are present, the patient should be considered to be at high risk regardless of the BMD result.
  17. Speaker Notes:
  18. Based on her history, this patient would be in a Moderate Risk category
  19. Speaker Notes; Shown another way, this is where this patient plots on the graph
  20. Speaker Notes: Using the 10 year fracture risk model, locate her age and T-score on the table. She is in a moderate risk category.
  21. Based on her history, this patient would be in a Moderate Risk category
  22. However, if she also presented with a fragility fracture, which is major risk factor for future fractures, she would move from Moderate Risk to High Risk (see next slide for table)
  23. Speaker Notes: Case Study: A 52 year old woman Menopause at age 49 Family History of osteoporosis (eg. Mother had fractured a hip at age 72) T-score: Hip –2.7 SD ; Lumbar Spine –2.0 SD The lowest T-score is used to assess BMD
  24. Based on her history, this patient would be in a Moderate Risk category
  25. However, if she also presented with a fragility fracture, which is major risk factor for future fractures, she would move from Moderate Risk to High Risk (see next slide for table)
  26. Speaker Notes: These recommendations have been endorsed by, and are being incorporated into, the following associations
  27. If your doctor says that you have or are at risk for osteoporosis, here are the most common medications he or she may prescribe. Today, I’m going to talk about Actonel. Note: Evista (raloxifene HCI) is a registered trademark of Eli Lilly Company. (Pronounced eee-vis-ta) Miacalcin (calcitonin salmon) Nasal Spray is a registered trademark of Novartis Pharmaceuticals Corporation. (Pronounced me-a-cal-sin) Fosamax (alendronate sodium tablets) is a registered trademark of Merck &amp; Company, Inc. (Pronounced foss-a-max) FOR ADDITIONAL INFORMATION ON ACTONEL AND OSTEOPOROSIS, PLEASE READ ACTONEL PATIENT INFORMATION.
  28. Speaker notes Reference Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271.
  29. Charles Montgomery Burns
  30. This was reported to CBC Health news update, from a researcher Dr. John Schousboe, a rheumatologist from the university of Minnesota and director of the osteoporosis centre ( at park Nicollet Health Services) in Minneapolis; he had worked in collaboration with authors from the university of California at San Francisco, the Oregon Health sciences University, Portland, and from the Mayo Clinic in Rochester, Minnesota
  31. This paper was to be published in JAMA the following day, 8 August 2007
  32. Risk of a woman dying is 20 – 25 % within 18 months after a hip fracture